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Abstract: Noncirrhotic portal hypertension (NCPH) is an uncommon liver disease 
of unknown origin, increasingly described in HIV-infected adults. Prolonged 
antiretroviral exposure, in particular to didanosine, and thrombophilic 
predisposition have been suggested as potential pathogenic factors. Data are scant 
in children. We describe a 10-year-old HIV-infected girl with NCPH who presented 
with progressive spleen enlargement and variceal bleeding. 
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Mortality and morbidity from AIDS-defining disease have decreased dramatically 
since the introduction of highly active anti-retroviral therapy (HAART) in HIV-
infected adults and children 1,2. As HIV-infected patients live longer, serious non 
AIDS-defining disease become increasingly important. Novel clinical 
manifestations or entities may emerge. A series of HIV-infected adults with 
symptomatic noncirrhotic portal hypertension (NCPH) has recently been described 
and half of those who underwent histological evaluation showed features 
compatible with nodular regenerative hyperplasia (NRH) and hepatoportal sclerosis 
(HPS) 3-7. The following is the description of an HIV-infected girl with a history of 
splenomegaly who developed NCPH and variceal bleeding. 
The patient is a 10-year-old white girl diagnosed with vertically acquired HIV 
infection at 19 months of age after both parents were diagnosed with HIV infection. 
HAART was commenced at 2 years of age with zidovudine, nevirapine and 
lamivudine because of decreased CD4+ count (331 cells/mm3). After 9 months, the 
antiretroviral regimen was modified to didanosine, tenofovir disoproxil fumarate 
and  lopinavir/ritonavir, due to virological failure. She achieved good virological 
and immunological control while on this regimen and her growth and development 
were normal. She was known to have thalassemic trait and iron-deficiency anemia, 
for which she received oral iron supplementation. At age 10 years, the patient 
developed progressive spleen enlargement; in June 2011 her spleen was palpable at 
10cm below the left costal margin, and her liver was not enlarged. At the time of 
splenomegaly diagnosis, the cumulative exposure to the current antiretroviral 
treatment was 7 years, HIV-RNA was undetectable (<37 copies/mL) and CD4+ 
count was 425 cells/mm3. 
The child did not have jaundice, encephalopathy or other stigmata of liver disease. 
She had no known exposure to toxins or drugs other than mentioned.  
Laboratory investigations documented a white blood cell count of 5380/mm3, 
hemoglobin of 8.5 g/dl, platelet count of 154000/mm3, international normalized 
ratio of 1.28, total bilirubin of 0.79 mg/dL, direct bilirubin of 0.29 mg/dL, albumin 
of 3.5 g/dL, serum alanine aminotransferase of 48 IU/L, serum aspartate 
aminotransferase of 52 IU/L, γ-glutamyl transferase of 35 IU/L, alkaline phospatase 
of 231 IU/L. Serum blood urea nitrogen and creatinine were normal. D-dimers were 
moderately elevated at 577 ng/dL (normal value < 250 ng/dL). Hypercoagulability 
studies demonstrated mild decreases in protein C (antigen and function both 49% of 
normal) and free protein S antigen (60% of normal). No significant abnormalities of 
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homocysteine, activated protein C resistance, antithrombin III or antibodies to 
cardiolipin were detected. Genetic analysis did not reveal Factor V Leiden, 5, 10 
methylenetetraydrofolate reductase, or prothrombin genetic mutations predisposing 
to thrombosis. 
Moreover, hepatitis B or C virus infections were ruled out on the basis of negative 
serological and molecular tests (COBAS Ampli Prep, Roche Diagnostics, 
Indianapolis, IN; Branched DNA, Siemens Medical Solutions, Berkley, CA, USA). 
Circulating autoantibodies (anti-mitochondrial antibodies [AMA], anti-nuclear 
antibodies [ANA], anti-smooth muscle antibodies [ASMA], anti-liver kidney 
microsomes antibodies [LKM]) were not detected. Levels of α-1 antitrypsin, α –
fetoprotein and ceruloplasmin were normal.  
Abdominal ultrasonography showed diffuse dishomogeneous hepatic parenchyma, 
coarse and nodular pattern at segment IV and mild parietal fibrosis of intrahepatic 
portal veins. Splenomegaly (>20cm span) and mild ascites (15mL) were also noted. 
Color Doppler demonstrated hepatofugal flow in the portal and splenic venous 
system as well as suprahepatic vein patency and paraesophageal collateral 
circulation.  
Magnetic resonance imaging revealed a heterogeneous liver with multiple sclerotic 
nodules. Paraesophageal and perisplenic collaterals as well as ascites were also 
noted.  
Esophagogastroduodenoscopy (EGDS) documented multiple -grade 2 esophageal 
varices without red wale marks and portal gastropathy without active bleeding. 
Transjugular suprahepatic catheterization revealed a normal hepatic vein pressure 
gradient (HVPG: 3.8mmHg, normal < 4mmHg) and allowed liver biopsy to be 
performed.  
Histological evaluation showed complete absence of normal portal vein branches in 
portal tracts which were replaced by small slit-like vessels (Figure 1a), mild to 
moderate macrovacuolar steatosis, focal sinusoidal fibrosis (Figure 1b) and central 
mild to moderate venulosclerosis (Figure 1c).  
On the whole, ultrasound images, EGDS findings and histological features were 
consistent with noncirrhotic portal hypertension and hepatoportal sclerosis. After 
extensive evaluation of other causes, the role of antiretroviral toxicity (particularly 
didanosine exposure) was hypothesized as a possible contributor to this condition.   
Therefore, the HAART regimen was changed to darunavir/ritonavir and etravirine. 
During the four months after change in HAART regimen, the patient was clinically 
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stable, maintained undetectable HIV-RNA and CD4+ cell count ranging from 364 to 
471 cell/mm3. The scheduled clinical follow-up included assessment of liver 
function and hepatic ultrasound imaging every three months, and EGDS every six 
months.  
Three months later, liver function tests and abdominal ultrasonography did not show 
disease progression. At endoscopy, 6 months later, red wale marks were observed 
on variceal walls. After one month the patient presented hematemesis and was taken 
to the emergency department. Esophagogastroduodenoscopy revealed multiple-
grade 3 esophageal varices; band ligation was performed, and propanolol was 
initiated. Since discharge she has been well and has not had hematemesis or melena. 
Her scheduled follow-up includes subsequent endoscopies for variceal monitoring 
and further banding, regular evaluation of liver function for any elevation of 
transaminases or reduced hepatic function and liver imaging for monitoring of portal 
hypertension and ascites. In the case of repeated serious complications of portal 
hypertension (i.e serious variceal bleeding),  transjugular intrahepatic portosystemic 
shunt (TIPS) would be a feasible option for the patient. 
DISCUSSION 
NCPH in HIV-infected adult population has attracted much attention over the last 5 
years, following the original description by Maida et al. of 9 subjects with severe 
liver disease of unknown origin presenting with portal hypertension complicated by 
variceal bleeding, ascites and/or hepatic encephalopathy 8. Over the last four years 
around 90 additional HIV-infected adult patients with NCPH have been reported 
5,6,9
. In the majority of these patients liver function tests were generally well 
preserved with normal albumin, bilirubin, prothrombin levels and mildly elevated 
serum aminotransferases and alkaline phosphatase. Pathological findings included 
the absence of advanced liver fibrosis and presence of narrowed and/or obliterated 
portal veins (hepatoportal sclerosis, HPS) and multiple small nodules (nodular 
regenerative hyperplasia, NRH). Prolonged prior exposure to didanosine was 
uniformly recognized. Recently Kochin et al. described a case of a 15-year-old HIV-
infected boy with prolonged exposure to didanosine who presented with variceal 
bleeding and was found to have HPS and NRH on liver biopsy 10.  
Here we describe the second case of NCPH in HIV-infected pediatric population. 
Our patient like the first pediatric case and the HIV-infected adult cases of NCPH, 
had prolonged exposure to didanosine. Additionally, she had, as shown in some 
adult HIV-infected cases of NCPH, mild protein S and C deficiency. This finding 
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supports the proposed hypothesis of a pathological role of prothrombotic state in 
development of NCPH. NCPH should be considered an emerging non-AIDS 
comorbidity in pediatric HIV infection that is likely related to treatment, particularly 
with didanosine, and other factors.  
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Figure Legends 
Fig 1. A. Portal tract. Slit-like portal vein  branch (arrow). H&E stain. Fig 1. B. 
Central vein fibrosis and sinusoidal fibrosis. Sirius-Red stain. Fig 1. C. Central 
vein. Moderate degree of fibrosis (arrows). H&E stain. 
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